Our Journey

Tracking a decade of biosensor innovation from 2016 to 2026

Explore

Timeline

A Decade of Innovation

Tracking our journey from the first competition in 2016 to our current focus on Parkinson's disease monitoring

2026
Current

Parkinson's Disease

Biomarker: Levodopa

SensUs 2026 aims to track levodopa fluctuations through continuous monitoring. This will help personalize treatment for Parkinson's disease patients and make a step towards closed-loop levodopa therapy!

2025

Kidney Failure (Continuous)

Biomarker: Creatinine

The topic of the previous year was continued, with stricter biosensor requirements than 2024, so that the teams could achieve next-level results in the novel area of continuous creatinine sensing.

2024

Kidney Failure (Continuous)

Biomarker: Creatinine

2024 was a throwback to the first edition of SensUs, namely biosensors to detect creatinine for kidney failure. Continuous monitoring was implemented for the first time, representing a significant advance toward personalized healthcare.

2023

Traumatic Brain Injury

Biomarker: GFAP

GFAP is a biomarker for Traumatic Brain Injury (TBI). It can reach high concentrations in TBI, resulting in physical, cognitive, social, emotional, and behavioral symptoms. Recovery outcomes range from complete recovery to permanent disability or death.

2022

Acute Inflammation

Biomarker: Interleukin-6

Interleukin-6 is a biomarker for acute inflammation and it can reach high concentrations in case of sepsis, a life-threatening condition triggered by infection. IL-6 measurement supports early diagnosis and monitoring.

2022
Milestone

First Distributed Testing Event

A new initiative allowed teams to prepare for the Eindhoven Testing Event under real competition conditions at their own universities.

2021

Respiratory Viruses

Biomarker: Hemagglutinin

Focus on detecting influenza A virus. The Covid-19 pandemic made it apparent that large virus outbreaks can cause immense harm to human health. Biosensors could help prevent respiratory virus spread.

2020
Milestone

First Online SensUs Innovation Days

Due to the coronavirus pandemic, the SensUs Innovation Days could not be organized physically. The event transitioned to a virtual environment.

2020

Epilepsy

Biomarker: Valproate

Valproate (VPA) is a drug used in the treatment of epilepsy, bipolar disorder and spinal muscular atrophy. Epilepsy affects around 50 million people worldwide. A biosensor could personalize VPA treatment and improve quality of life.

2019

Rheumatoid Arthritis

Biomarker: Adalimumab

Adalimumab is a biological drug that is prescribed to patients suffering from rheumatoid arthritis (RA). Measurement of concentrations enables more efficient disease management for this condition affecting approximately 1% of the global population.

2018

Antibiotics

Biomarker: Vancomycin

Teams developed biosensing systems for measuring the antibiotic drug vancomycin. The innovation addresses anti-microbial resistance by helping provide patients precise dosing to maximize effectiveness while reducing side effects.

2017

Heart Failure

Biomarker: NT-proBNP

Heart failure is a very important public health problem in both developed and developing countries with a prevalence of about 1% of the population. NT-proBNP serves as a key biomarker for this condition.

2016

Kidney Failure

Biomarker: Creatinine

Biosensors for kidney failure detection. Creatinine is a waste molecule that is filtered out of the blood by the kidneys. Monitoring enables patients to track kidney health rapidly and conveniently.

Be Part of Our Journey

Join the next generation of innovators pushing the boundaries of biosensor technology

Explore Theme 2026 View Teams